Search Results

PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation, a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, announced the appointment of Fred Paster as Head of Commercial.

PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology, oncology and immunology, today announced completion of enrollment for two clinical trials evaluating its ropeginterferon alfa-2b-njft (BESREMi®).

IDBS announced that it has entered into a partnership with Massachusetts-based PharmaEssentia Innovation Research Center on its Polar platform to help digitize data management and facilitate collaboration between the company’s global research and development teams.

PharmaEssentia USA Corporation announced that the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology have recently been updated to include ropeginterferon alfa-2b-njft, marketed as BESREMi®, as a preferred first-line cytoreductive therapy option for the treatment of adults with symptomatic, low-risk polycythemia vera.

PharmaEssentia Corporation announced the company is included in the FTSE Global Equity Index Series, FTSE All-World Index, FTSE global All-Cap and total-Cap Indices, and the FTSE Global Mid Cap Index.

PharmaEssentia Corporation , today announced it has entered into a license agreement with WuXi Biologics Ireland Limited to obtain the global exclusive rights to research, develop, manufacture and commercialize a myeloid immune checkpoint antibody candidate.